- Home
- BAFN vs CGTX Comparison
BAFN vs CGTX Comparison
Compare BAFN & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAFN
- CGTX
- Stock Information
- Founded
- BAFN 1999
- CGTX 2007
- Country
- BAFN United States
- CGTX United States
- Employees
- BAFN N/A
- CGTX N/A
- Industry
- BAFN Savings Institutions
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- BAFN Finance
- CGTX Health Care
- Exchange
- BAFN Nasdaq
- CGTX Nasdaq
- Market Cap
- BAFN 63.2M
- CGTX 53.4M
- IPO Year
- BAFN N/A
- CGTX 2021
- Fundamental
- Price
- BAFN $8.78
- CGTX $2.37
- Analyst Decision
- BAFN
- CGTX Strong Buy
- Analyst Count
- BAFN 0
- CGTX 3
- Target Price
- BAFN N/A
- CGTX $2.83
- AVG Volume (30 Days)
- BAFN 24.3K
- CGTX 12.1M
- Earning Date
- BAFN 10-23-2025
- CGTX 08-07-2025
- Dividend Yield
- BAFN 3.74%
- CGTX N/A
- EPS Growth
- BAFN 100.65
- CGTX N/A
- EPS
- BAFN 1.89
- CGTX N/A
- Revenue
- BAFN $78,211,000.00
- CGTX N/A
- Revenue This Year
- BAFN N/A
- CGTX N/A
- Revenue Next Year
- BAFN N/A
- CGTX N/A
- P/E Ratio
- BAFN $4.60
- CGTX N/A
- Revenue Growth
- BAFN 0.67
- CGTX N/A
- 52 Week Low
- BAFN $6.40
- CGTX $0.22
- 52 Week High
- BAFN $19.75
- CGTX $3.83
- Technical
- Relative Strength Index (RSI)
- BAFN 38.58
- CGTX 62.29
- Support Level
- BAFN $8.36
- CGTX $2.28
- Resistance Level
- BAFN $10.16
- CGTX $3.83
- Average True Range (ATR)
- BAFN 0.85
- CGTX 0.43
- MACD
- BAFN 0.17
- CGTX 0.01
- Stochastic Oscillator
- BAFN 58.19
- CGTX 45.62
About BAFN BayFirst Financial Corp.
BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.